drugset / Trial / NCT00043433

Study of T900607-Sodium in Chemotherapy Naive Patients With Hepatocellular Carcinoma.

NCT00043433 ↗

Phase 2 Unknown 35 enrolled Tularik
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to determine whether T900607-sodium is effective and safe in treating hepatocellular carcinoma, a type of liver cancer.

Timeline

Start
2002-07
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject T900607 Small molecule — Intravenous